news
Roche subcutaneous cancer immunotherapy granted MHRA approval
The first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain on the NHS reduces treatment time to under ten minutes.
List view / Grid view
Halozyme Therapeutics
news
Ten-minute subcutaneous injection shows promise for MS
A Phase III trial for the only therapy approved for both relapsing and primary progressive multiple sclerosis (MS) met its clinical endpoints, Genentech has announced.
article
HIV treatment evolution: drug development to meet the modern needs of patients
In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
news
Collaboration to develop ultra-long acting medicines for HIV
ViiV Healthcare is licencing Halozyme’s Enhanze® drug delivery technology to help develop ultra-long acting versions of its long-acting HIV pipeline products.
news
First patient dosed in Halozyme’s PEGPH20 pancreatic cancer trial
17 March 2016 | By Victoria White
The trial will study PEGPH20 in combination with nab-paclitaxel and gemcitabine in patients with tumours that accumulate high levels of hyaluronan...
news
Eisai and Halozyme to investigate Halaven and PEGPH20 in metastatic breast cancer
31 July 2015 | By Victoria White
Eisai and Halozyme are to collaborate to evaluate Halaven in combination with PEGPH20 in first line HER2-negative metastatic breast cancer...
